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Weight gainTamoxifen (TAM) is a selective estrogen receptor modulator (SERM) used in the treatment of breast cancer;
however many women complain of weight gain during TAM treatment. The anorectic effects of estradiol (E)
and TAM are well known, although the effects of E on the consumption of palatable food are controversial
and there is no information regarding the effects of TAM on palatable food consumption. The aim of this
study was to investigate the effects of chronic treatment with estradiol and/or tamoxifen on feeding behavior
in ovariectomized rats exposed to standard chow and palatable foods (Froot Loops® or chocolate). Additionally,
parameters such as body weight, uterine weight, lipid proﬁle and plasma glucose were also measured. Wistar
rats were ovariectomized (OVX) and subsequently injected (ip.) for 40 days with: E, TAM, E + TAM or vehicle
(OVX and SHAM – controls). Behavioral tests were initiated 25 days after the start of treatment. Froot Loops®
consumption was evaluated in a novel environment for 3 min. Standard chow intake was evaluated for two
days and chocolate intake for 7 days in the home cage in a free choice model (chocolate or standard chow).
Rats injected with E, TAM and E + TAM groups showed a reduction in body weight and standard chow intake,
compared with control groups. With regard to palatable food intake, the E, TAM and E + TAM groups demon-
strated increased consumption of Froot Loops®, compared with the SHAM and OVX groups. In contrast, all
groups increased their consumption of chocolate, compared with standard chow; however the E group con-
sumed more chocolate than the OVX, TAM and E + TAM groups. Despite these differences in chocolate con-
sumption, all groups showed the same caloric intake during the chocolate exposure period; however the
TAM and E + TAM groups presented decreased body weight. Treatment with estradiol and tamoxifen showed
a favorable lipid proﬁle with low levels of TC, LDL, LDL/HDL ratio and lower levels of plasma glucose. The E
group presented high levels of TG and HDL, when compared with the TAM and E + TAM groups. Taken togeth-
er, results suggest that TAM acted in an estrogen-likemanner on themajority of parameters analyzed. However,
tamoxifen acts in a different manner depending on the type of palatable food and the exposure. In addition, the
TAM group demonstratedweight loss, comparedwith other groups independently of the type of food presented
(palatable food or standard chow), showing a low caloric efﬁciency.
© 2013 Elsevier Inc. All rights reserved.a, ICBS, UFRGS, Ramiro Barcelos,
razil. Tel.: +55 51 3308 5570;
).
rights reserved.1. Introduction
Tamoxifen (TAM) is a triphenethylene derivative drug that is
widely used for the treatment of all stages of breast cancer [1], reduc-
ing the incidence of breast cancer in both pre and postmenopausal
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modulator (SERM), a class of drugs that act as estrogen receptor ago-
nists or antagonists, depending on the target tissue [4]. TAM behaves
like an estrogen antagonist in mammary tissue while it mimics the
effects of estrogen in other tissues, for example the uterus, cardiac
and bone tissues [5–7]. However, it is not yet understood whether
TAM has estrogenic or antiestrogenic activities in the brain.
Estrogens exert their physiological effects through two estrogen
receptor (ER) subtypes, ERα and ERβ, which belong to the nuclear
receptor family of ligand-activated transcription factors. ER has two
‘activation’ domains within the receptor, which facilitate the interac-
tion of the ER with the transcription apparatus-activation function-1
(AF-1) and activation function-2 (AF-2). Both ERα and ERβ contain
an AF-2 domain, but unlike ERα, ERβ seems to have a weaker AF-1
domain and depends more on the AF-2 for its transcriptional activa-
tion function [8,9]. Furthermore, estrogen can act by non-genomic
mechanisms via membrane ERs [10]. Evidence suggests that tamoxi-
fen inhibits ER-AF-2 activity, and consequently acts as an antagonist
in ERβ and has partial agonist activity in ERα [11].
In addition to the estrogen effects on reproductive physiology, this
ovarian hormone can modulate numerous brain neurotransmitters
and neuromodulators, including the serotonergic, dopaminergic,
neuropeptide Y and opioidergic systems, and consequently modulate
cognitive functions, mood and the reward system [12–14]. It is well
established that estradiol reduces food intake, body weight and
improves lipid proﬁle, possibly via the activation of ERα [15,16].
These effects are probably due to an increase in the expression of
anorexigenic genes and a decrease in the expression of orexigenic
genes [17]. It iswell known that tamoxifenmimics the effects of estradiol
on food intake in rats [18,19].
Apart from these well-established effects of estradiol on food
intake, the role of estradiol on palatable food is controversial and
more complex [20,21]. Palatable foods activate the reward system,
thereby affecting ingestive behavior [22,23]. The predilection for palat-
able foods and reward system activation is a basic and evolutionarily-
conserved survival mechanism in animals and humans [24]. Foods
rich in fat and sugar are attractive because such foods can be rapidly
converted into energy [24,25]. It has been demonstrated that the prefer-
ence for palatable foods, including sweets, differs between males and
females, and sweet preferences change across the menstrual cycle and
during pregnancy [20,26–30]. However, other studies report that estro-
gen does not affect behavioral responses to palatable foods [21,31].
Although it is well established that tamoxifen-treated animals
demonstrate reduced body weight and standard chow intake, there
is no information in the literature regarding tamoxifen treatment
and the consumption of palatable food. On the other hand, humans
have access to a variety of fat and sweet foods and it is known that
many women experience weight gain during tamoxifen treatment
for breast cancer. This is especially true for patients who were not
overweight before diagnosis [19,32].
Therefore, the aim of this study was to investigate the effects of
chronic treatment with estradiol and/or tamoxifen on feeding behav-
ior in ovariectomized rats exposed to standard chow and palatable
foods (Froot Loops® or chocolate). Additionally, parameters such as
body weight, uterine weight and lipid proﬁle were also measured.
2. Methods
2.1. Animals
We used 120 adult female (7–13 per group), Wistar rats (75 days
of age at the beginning of the treatment), weighing between 180 and
220 g. Rats were housed in groups, with ﬁve rats per cage. Cages were
made of Plexiglas material (65 × 25 × 15 cm) with the ﬂoor covered
with sawdust. Animals were maintained on a standard dark–light
cycle (lights on between 7:00 h and 19:00 h), at a room temperatureof 21 ± 1 °C. The rats had free access to food (standard rat chow) and
water. All experimental procedures occurred during the light phase
(10:00–15:00 h). All animal treatments were in accordance with
the institutional guidelines and according to the recommendations
of the International Council for Laboratory Animal Science (ICLAS),
and all efforts were made to minimize animal suffering, as well as
to reduce the number of animals used.2.2. Surgery
All rats were ovariectomized or just underwent the surgery without
removal of ovaries (SHAM group). Ovariectomies were performed
under aseptic conditions. Rats were anesthetized with 60 mg/kg keta-
mine HCl (Dopalen: Agribrands, Campinas, SP, Brazil) and 16 mg/kg
xylazine (Anasedan: Agribrands, Campinas, SP, Brazil) ip., and bilateral
ovariectomy was performed with a single abdominal incision. The
abdominal skinwas then cut, the peritoneumwas opened, both ovarian
arteries were linked, and both ovaries were removed. The muscle and
the skin were sutured [33]. Animals received one drop of acetamino-
phen (200 mg/ml, Paracetamol EMS, Hortolândia, SP, Brazil) after sur-
gery as analgesic.2.3. Treatments
After a recovery period of 10–15 days, the animals received Froot
Loops® or chocolate in their home cage, 24 h before beginning the
treatments in order to avoid taste aversion [34,35]. The animals
were divided into ﬁve groups: SHAM group (submitted to the surgery
without removal of ovaries and received vehicle), OVX group
(received vehicle), 17β-estradiol group (OVX that received 0.1 mg/kg),
tamoxifen group (OVX that received 2 mg/kg) and E + TAM (OVX
that received 0.1 mg/kg of 17β-estradiol + 2 mg/kg of tamoxifen).
Tamoxifen (PharmaPlus — Porto Alegre, RS, Brazil) and estradiol
(Sigma — St. Louis, MO, USA) was dissolved in vehicle: ethanol (10%),
DMSO (5%) and 0.9% NaCl (85%). It is important to note that the
2 mg/kg dose of tamoxifen used in the present study is calculated to
be the equivalent dose that is prescribed to patients (20 mg), based
on surface area (mg/m2) [34]. The 0.1 mg/kg dose of estradiol was
chosen based on previous studies [36], and mimics the proestrus
phase of the estrous cycle [37]. Rats were injected (1 ml/kg ip.) daily
between 1:00 pm and 3:00 pm until euthanasia. Body weight was
monitored once a week.2.4. Exposure to sweet food
The behavioral test was initiated 25 days after the ﬁrst injection.
Prior to all tests, rats were acclimatized to the experimental room
for at least 30 min. This food behavior was conducted during the
light phase [28,38], in order to measure the consumption of sweet
food regardless of physiological mechanisms of hunger.
Rats were placed in a rectangular box (40 cm × 15 cm × 20 cm)
with ﬂoor and side walls made of wood and a glass ceiling. Ten
Froot Loops® (Kellogg's® pellets of wheat, cornstarch and sucrose)
were placed in one extremity of the box. The animals were habituated
to this environment for 5 days, for 3 min each day, under food restric-
tion (receiving 80% of habitual ingestion). After the last habituation
session, the animals were fed ad libitum and were exposed to a
3-min test session, 24 h later. Time spent to reach the food, time
spent until beginning to eat and the number of ingested Froot
Loops® were evaluated in each trial and in the test session. A protocol
was established so that when the animals ate part of the Froot Loops®
(e.g., 1/3 or 1/4), this fraction was considered [38]. This experiment
could mimic the problem of women that gain weight during TAM
treatment and diet in order to lose weight using food restriction.
Fig. 1.Weight change (g) during 28 days of treatment. Data are expressed as mean ±
SEM. *p b 0.0001, signiﬁcantly different from control groups (SHAM and OVX).
Table 1
Nutritional composition per 100 g of food used in the study.
Food Energy
(kcal)
Total
protein
(g)
Total
carbohydrate
(g)
Total
fat
(g)
Chocolate Neugebauer® 516 3.2 64 27.2
Rat chow Nuvilab CR-1® 324 22 55 4.5
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Twenty ﬁve days after the ﬁrst injection, the animals were sepa-
rated with two animals from the same group per cage and the con-
sumption of standard chow was measured for two days. On the
third day, the animals received standard chow and chocolate ad
libitum, allowing them to choose between the two types of food for
the next 7 days. The food was previously weighed and the remaining
quantity was measured each day to evaluate consumption. See
Table 1 for nutritional composition of these foods. To determine the
caloric efﬁciency, (the amount of body weight gained as a result of
caloric intake), the body weight gain (in milligrams) was divided by
the total amount of kilocalories consumed over the 7 days [39]. For
this experiment we used a different set of animals.
2.6. Blood collection and structure dissection
One day after the last behavioral procedure, animals were killed
by decapitation after 14 h of fasting, between 09:00 h and 15:00 h,
and the trunk blood was collected into tubes with EDTA, centrifuged
at 4 °C/1000 g, and plasma separated and stored at −80 °C until
analysis of plasma lipids and plasma glucose. Uterus and retroperito-
neal fat were carefully dissected and weighed using a scale with a
precision of 0.0001 g.
2.7. Plasma lipids and glucose (Blood Biochemistry)
Total cholesterol (TC), high-density lipoprotein cholesterol (HDL),
and triglyceride analyses were performed on EDTA plasma, collected
from animals fasted for 14 h before blood collection. TC and triglycer-
idesweremeasured by enzymaticmethod kits (Wiener Lab, Argentina).
HDL concentrations were measured by a system for selective precipita-
tion of Low andVery LowDensity Lipoproteins (LDL and VLDL) andHDL
cholesterol measurement in the supernatant, using an end point reac-
tion, as described in the HDL Kit (Labtest, Brazil). Low-density lipopro-
tein cholesterol (LDL)was calculated using the Friedewald formula [40].
Plasma glucose was measured by the glucose oxidase method (Wiener
Laboratories, Rosario, Argentina). All analyses were performed on a
Spectra Max M5 autoanalyzer. For this experiment we used a different
set of animals.
2.8. Statistical analyses
Data were analyzed using one-way or repeated-measures analysis
of variance (ANOVA) and were expressed as means ± SEM. When
indicated, a post-hoc Duncan multiple range test was performed.
Signiﬁcance levels for all measures were set at p b 0.05.
The timeline of the experimental procedures is shown below.
3. Results
3.1. Body weight, retroperitoneal fat and uterine weight
SHAM and OVX groups presented an increase in body weight
(F(4,34) = 46.56, p b 0.001) and retroperitoneal fat (F(4,48) =
4.91, p = 0.002), and these effects were prevented by chronicadministration of E, TAM or E + TAM (F(4,34) = 46.56, p b 0.001)
(Fig. 1 and Table 2).
Ovariectomized rats that received vehicle presented a signiﬁcantly
decreased uterine weight, when compared with the SHAM group.
Those animals treated with estradiol demonstrated a signiﬁcantly
increased uterine weight, whereas TAM and E + TAM were unable
to reverse the uterine weight loss due to ovariectomy (F(4,35) =
9.11, p b 0.001) (Table 2).
3.2. Standard chow intake
We observed that the consumption of standard chow in the home
cage was lower in groups treated with E, TAM or E + TAM (F(4,17) =
4.5, p = 0.01). The caloric efﬁciency of these groups was also lower
(F(4,13) = 16.8, p b 0.0001), compared with the SHAM and OVX
groups (Fig. 2A and B).
3.3. Sweet food ingestion
A one-way ANOVA, followed by the Duncan multiple range test,
showed that the E, TAM and E + TAM groups took less time to reach
the Froot Loops® (F(4,44) = 5.49, p b 0.001) (Fig. 3A) and start to
eat (F(4,41) = 2.73, p = 0.001) (Fig. 3B). E, TAM and E + TAM
increased their intake of Froot Loops® (F(4,41) = 5.58, p = 0.01),
compared to the SHAM and OVX groups (Fig. 3C).
3.4. Exposure to chocolate and standard chow
When chocolate and standard chow were offered in the home
cage, one-way ANOVA showed that the consumption of chocolate
was higher in the E group, compared with the OVX, TAM and
E + TAM groups (F(4,13) = 4.15, p = 0.02). No differences were
seen among groups regarding the consumption of standard chow
for 7 days (F(4,13) = 1.8, p = 0.19) (Fig. 4A). During exposure to
standard chow and chocolate, all groups showed an increase in total
calories consumed per day and there were no signiﬁcant differences
among the groups (F(4,14) = 278, p b 0.001), unlike those observed
Table 2
Retroperitoneal fat and uterine weight.
SHAM OVX E TAM E + TAM
Retroperitoneal fat (g) 3.2 ± 0.3 3.3 ± 0.4 2.3 ± 0.2a 2.2 ± 0.3a 1.8 ± 0.1a
Uterine weight (mg) 414.9 ± 59.6a 189.1 ± 48.7 386.8 ± 39.0a 190.5 ± 26.9 253.8 ± 26.2
Data are shown as mean ± SE.
a Indicates statistical differences (p b 0.05) among groups.
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Although the same amounts of calories were consumed during the
exposure to standard chow and chocolate, the OVX group showed
the greatest weight gain and caloric efﬁciency, followed by the E,
SHAM and TAM groups, while the E + TAM group presented weight
loss (F(4,33) = 18.6, p b 0.0001) (Fig. 4C) and lower caloric efﬁ-
ciency (F(4,10) = 24.67, p b 0.0001) (Fig. 4D).3.5. Blood Biochemistry
Ovariectomy caused an increase in total cholesterol (F(4,27) =
5.81, p = 0.001) and LDL cholesterol (F(4,27) = 5.72, p = 0.002)
levels and this was prevented by the administration of estradiol and
tamoxifen. The OVX, TAM and E + TAM groups demonstrated lower
levels of HDL cholesterol (F(4,27) = 4.48, p = 0.006), compared to
the SHAM and E groups. TAM treatment reduced triglyceride levels
(F(4,27) = 5.77, p = 0.002) and prevented the effect of estradiol
on this parameter. The TAM treatment group also presented the low-
est plasma glucose levels, followed by E + TAM and estradiol groupsFig. 2. Standard chow consumption for 2 days (kcal/100 g of rat weight) (A) and caloric
efﬁciency (mg of weight/kcal/day) (B). Data are expressed as mean ± SEM. *p b 0.05
signiﬁcantly different from control groups (SHAM and OVX).(F(4,26) = 8.3, p b 0.001). The OVX group showed a higher LDL/HDL
ratio, compared with the other groups (F(4,27) = 4.7, p = 0.005)
(Table 3).Fig. 3. Consumption of sweet food (Froot Loops®) during the feeding behavior (with
animals previously fed ad libitum). Latency to reach until Froot Loops (A). Latency to
begin to eat the Froot Loops (B). Number of Froot Loops consumed in 3 min (C). Data
are expressed as mean ± SEM. *p b 0.05, signiﬁcantly different from control groups
(SHAM and OVX). **p b 0.05, signiﬁcantly different from the others groups. &p b 0.05,
signiﬁcantly different from OVX group.
Fig. 4. Standard chow and chocolate consumption for seven days (total kcal/100 g of rat weight) (A). Proﬁle of food intake (kcal/100 g of rat weight/day) during the exposition to
just standard chow and exposition to standard chow plus chocolate (B). Weight change during the exposition to chocolate (C). Caloric efﬁciency during the exposition to chocolate
(D). Data are expressed as mean ± SEM. §p b 0.05, signiﬁcantly different from OVX, TAM and E + TAM groups. *p b 0.05, signiﬁcantly different from control groups (SHAM and
OVX). &p b 0.05, signiﬁcantly different from OVX group. #p b 0.05, signiﬁcantly different from E group.
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Chronic treatment of ovariectomized rats with estradiol and
tamoxifen led to a decrease in body weight, retroperitoneal fat and
a decrease in standard chow intake. The caloric efﬁciency was lower
for the E, TAM and E + TAM groups. When rats were exposed to a
palatable food, a different proﬁle was observed depending on the
type of palatable food. The E, TAM and E + TAM groups consumed
more Froot Loops® than the other groups. With regard to chocolate,
the E group consumed more calories from chocolate, when compared
with OVX, TAM and E + TAM groups. Chronic treatment with estra-
diol and tamoxifen showed a favorable lipid proﬁle; low levels of
TC, LDL, LDL/HDL ratio and lower levels of glucose were observed.
Levels of HDL were lower in the OVX, TAM and E + TAM groups.
The E group showed higher levels of TG and HDL, in contrast to the
TAM and E + TAM groups.
Although tamoxifen is considered an estrogen agonist in the
uterine tissue in women [41], the present study showed that tamox-
ifen, in contrast to estradiol, was unable to revert the uterine weight
loss induced by ovariectomy, and also inhibited the effect of estradiol.
These results are in agreement with another study showing that
tamoxifen has no effect on uterine weight [18]. However, other stud-
ies have shown that tamoxifen could partially reverse the uterineTable 3
Plasma lipids (mg/dL) and plasma glucose (mg/dL).
SHAM OVX
Total cholesterol 42.4 ± 2.8a,c 52.9 ± 3.6b
HDL cholesterol 21.6 ± 2.1a 16.2 ± 0.8
LDL cholesterol 26.6 ± 2.8 43.7 ± 3.6a
Triglyceride 37.4 ± 2.0a,b 44.6 ± 3.9a
LDL/HDL 1.2 ± 0.2 2.7 ± 0.2a
Plasma glucose 94.7 ± 5.7a 89.3 ± 2.3a
Data are shown as mean ± SE.
Different superscripts in the same row indicate statistical differences (p b 0.05) among groweight loss provoked by ovariectomy [42,43]. The reason for these
contradictory results on uterine weight is not well understood,
because TAM was effective as an estrogen agonist when measuring
the parameters, body weight loss and retroperitoneal fat (see below).
Ovariectomized rats and the SHAM group, which received the
vehicle, presented increased body weight and retroperitoneal fat,
whereas rats treated with estradiol and/or tamoxifen showed a
reduction in these parameters. These results are consistent with pre-
vious ﬁndings in the literature [10,18,19,21,34,35]. Estradiol and
tamoxifen treatment provoked a decrease in standard chow intake
in ovariectomized rats, as expected and in agreement with data
from literature [18,19,21,44]. The decrease in food intake associated
with TAM and E treatment undoubtedly contributed to the decrease
in body weight and fat content, but it is not clear whether hypophagia
can entirely explain the weight loss [18]. An important role of the
estradiol receptors (ERs), particularly ERα, in the reduction of body
weight, food intake and adipose tissue has been demonstrated
[15,45–47]. Adipocytes isolated from obese women have been
reported to present reduced ERα mRNA levels, compared to those
of non-obese women, suggesting that estrogen signaling, in particular
via ERα, may inﬂuence body weight [46]. ERα-deﬁcient mice
exhibited an increased adipose tissue mass without displaying differ-
ences in energy intake, suggesting that the weight gain is due to aE TAM E + TAM
43.7 ± 3.2c 33.7 ± 4.3a,d 36.6 ± 1.5a,c
21.6 ± 2.0a 14.3 ± 1.1 16.2 ± 1.3
31.6 ± 2.8 25.9 ± 3.4 27.1 ± 2.8
47.3 ± 4.2a 28.7 ± 2.8b 33.8 ± 2.9b
1.5 ± 0.2 1.9 ± 0.3 1.8 ± 0.3
82.3 ± 1.0b 74.4 ± 2.9c 79.9 ± 1.4b,c
ups.
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caloric efﬁciency of animals treated with estradiol and tamoxifen,
found in the present study. Since tamoxifen, as well as estradiol,
prevented any further weight gain, fat gain and food intake, it may
be suggested that tamoxifen acts as an estradiol agonist on these
parameters via ERα activation, given that tamoxifen is considered a
partial agonist of ERα [11]. In addition, estradiol and tamoxifen re-
duce lipoprotein lipase activity [49–51], which could contribute to
decreased fat deposition due to reduced fatty acid release for lipogen-
esis. In addition, weight loss may be due to the role of estrogen in
modulating uncoupling protein (UCP) in white adipose tissue. Estro-
gen can increase the expression of UCP2 in white adipose tissue and
increase the energy spent as heat [52].
We also found differences in the palatable food intake proﬁle
when rats were submitted to different kinds of exposure to palatable
foods (restrictive schedule to Froot Loops® or free access to choco-
late). During the exposure to sweet food (Froot Loops®), after
5 days of food restriction and under a restrictive schedule of exposure
to Froot Loops, rats treated with estradiol and/or tamoxifen increased
their consumption, compared with the control groups. Other studies
have also shown an increase in sweet food intake when estradiol
levels are high, as seen in the proestrus in rats [27] and in the follicu-
lar phase in women [15]. When the animals were exposed to choco-
late and standard chow in the home cage for 7 days with 24 h of
free access, all groups consumed more chocolate than standard
chow. In contrast, rats treated with estradiol ate even more chocolate
than the OVX, TAM and E + TAM groups, although the total caloric
consumption was the same in all groups. A similar observation was
made by Boswell et al. (2006) [20], who utilized a chocolate cake
mix and observed an increase in food intake in rats treated with estra-
diol. On the other hand, Butera et al. (2010) [21] observed that estra-
diol treatment caused a reduction in chocolate intake, in a treatment
paradigm that mimics the estrous cycle, instead of continuous
hormone replacement. Therefore, we found that tamoxifen acted in
a different manner, depending on the kind of palatable food and/or
the paradigm of exposure to food.
Independently of sex, both rats and humans are naturally more
susceptible to palatable foods. Food intake is regulated by several
factors; a homeostatic pathway that maintains energy sources and a
hedonic pathway that stimulates the desire to consume foods that
are palatable [23]. Palatable food can mobilize opioids and dopamine
and increase the levels of galanin, enkephalin, and orexin in the
reward system, stimulating overeating as a positive feedback
[23,25]. Estrogen is also able to interact with the reward system by in-
creasing the expression of orexin and galanin neurons in the hypo-
thalamus, which are involved in reward-based feeding behavior
[53–56]. The activation of these neurons promotes the release of
dopamine and an increase in palatable food intake [25,53,54]. This
stimulation in reward circuitry may occur through ERβ, given that
this receptor is able to modulate the dopamine receptor and dopa-
mine transporter in the striatum and accumbens nucleus [13] and it
is probably the estradiol receptor more related to the ingestion of
palatable foods [27]. Tamoxifen is known to have antagonist effects
in ERβ [11], and this could explain the difference in chocolate intake
between the tamoxifen and estradiol groups. In this sense, we specu-
late that estradiol could increase palatable food ingestion by stimula-
tion of the release of hormones and neuropeptides involved in reward
circuitry, independently of the satiety system; such an effect may
occur through ERβ. In addition, the TAM and E + TAM groups con-
sumed the same calories as the other groups during the exposure to
chocolate, but demonstrated a lower caloric efﬁciency.
Evaluation of Froot Loops consumption, unlike the evaluation of
chocolate consumption, involved a habituation period (5 days) and
during this period the animals were deprived of food (80%). On the
test day the animals were fed, but consumption was assessed as
before, using a restrictive schedule. Food deprivation stronglyaugments the reward value (for example, the speed of learning to ob-
tain a rewarding stimulus) [57]. However, the OVX and SHAM groups
showed a signiﬁcantly higher latency to eat and ate less, compared
with groups treated with estradiol and/or tamoxifen. Independently
from the hormonal milieu of the animal, food deprivation increases
the expression of neuropeptides Y (NPY) in the arcuate nucleus, con-
sequently more NPY is released in the paraventricular nucleus [58]
and these effects can be reversed by leptin administration [59]. Fur-
thermore, estradiol treatment reduces the circulating leptin levels,
and increases the leptin receptor and suppressor of cytokine signaling
3 (SOCS3, an inhibitor of leptin signaling) expressions in the medial
basal hypothalamus; however these effects were not observed in
OVX rats treated with vehicle [44]. Given that NPY is related to the
increase in high carbohydrate diet consumption [60], the food depri-
vation that rats underwent during the habituation period might have
been responsible for the higher consumption of Froot Loops in rats
treated with estradiol and tamoxifen. This effect was not observed
in the SHAM and OVX groups, probably due to the high circulating
leptin levels (which inhibit NPY), given that these groups have a
higher fat accumulation. NPY declines in relation to body fat, presum-
ably attributable to an increase in leptin levels [60]. Further studies
are needed to elucidate the mechanisms involved in the effects of
estradiol and tamoxifen on palatable food behavior.
Estradiol and tamoxifen treatment showed a favorable proﬁle
regarding plasma lipids and glucose. The estradiol and tamoxifen
groups presented a decrease in TC, LDL levels, and LDL/HDL ratio
and plasma glucose, compared to the OVX rats treated with vehicle;
however, the effect of TAM was more accentuated on TC and glucose
levels. The TAM and OVX groups presented lower HDL cholesterol
levels, compared with the estradiol group; however the difference in
LDL/HDL ratio in OVX rats was probably due to the high levels of LDL
in this group. The decrease in plasma LDL caused by estradiol may be
the result of increased hepatic LDL receptor expression [61–63]
which increases the clearance of plasma LDL and the secretion of cho-
lesterol into the bile. In addition, it has been demonstrated that this
LDL receptor transcription activation occurs via ERα [63], therefore,
tamoxifen may act by the same mechanism, increasing hepatic LDL
receptor expression [64] with a consequent decrease in LDL levels.
With regard to HDL levels, estrogen is known to increase plasma levels
of HDL cholesterol [65,66]. This may be due to an increase of hepatic
apo A-I expression [67,68] and by a modulation of the proteins
involved in the metabolism of HDL expression, such as HDL receptor
SR-BI [69,70]. However, the effect of tamoxifen is less conclusive,
because literature reports increase [71], decrease [64], or no change
[72] on HDL cholesterol levels. Moreover, differently from estradiol
treatment, the levels of SR-BI expression were not changed with
tamoxifen treatment [64]. However, despite the lower levels of HDL
shown in TAM group, the LDL/HDL ratio was equal to the estradiol
group and different from OVX rats treated with vehicle. It has been
shown that estradiol induces a decrease in lipoprotein lipase (LPL)
activity in adipose tissue [50,73] and this mechanism could, at least
in part, explain the elevated serum triglycerides found in estradiol
group. Tamoxifen also reduces the LPL activity in humans and rats,
but differently from estradiol, it did not elevate plasma triglyceride
levels [51], perhaps it can be due to a decrease in VLDL secretion. It
has been demonstrated that tamoxifen induces hepatic triacylglycerol
accumulation [64], probably due to an increase in the synthesis [74] or
a fatty acid oxidation blockade [64]. It could disturb the liver function
and reduce the secretion of VLDL.
5. Conclusion
Tamoxifen treatment mimicked the effects of estradiol in many
parameters: weight loss, retroperitoneal fat, standard chow intake
and in most lipids analyzed, but in the uterine weight TAM
behaved as estrogen-antagonist. Concerning the palatable food
23C. Lampert et al. / Physiology & Behavior 119 (2013) 17–24intake, TAM acted in a different manner depending on the experi-
mental conditions. Under restrictive schedule, TAM treated rats
ate as much Froot Loops as E group. Under free access, all groups
showed more preference to chocolate than standard chow, but E
group ate even more chocolate. Further, TAM group showed
lower caloric efﬁciency irrespective of the kind of food offered
(palatable or standard chow), showing that TAM group has greater
energy expenditure and in consequence it accumulates less fat than
the other groups.
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